Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | ATM | Q13315 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | PPM1B | O75688 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2534532 | 1.00 | CYP1A2 (0.60) | CYP1A2CYP2C9TSHRCYP2C19ALDH1A1 | |
| SCHEMBL7227981 | 1.00 | CYP1A2 (0.60) | CYP1A2CYP2C9TSHRCYP2C19ALDH1A1 | |
| SCHEMBL7220705 | 1.00 | CYP1A2 (0.60) | CYP1A2CYP2C9TSHRCYP2C19ALDH1A1 | |
| SCHEMBL986291 | 1.00 | CYP1A2 (0.60) | CYP1A2CYP2C9TSHRCYP2C19ALDH1A1 | |
| SCHEMBL2535775 | 0.88 | CYP1A2 (0.50) | CYP1A2CYP2C9TSHRCYP2C19ALDH1A1 | |
| SCHEMBL2534983 | 0.88 | CYP1A2 (0.50) | CYP1A2CYP2C9TSHRCYP2C19ALDH1A1 | |
| SCHEMBL2534980 | 0.88 | CYP1A2 (0.50) | CYP1A2CYP2C9TSHRCYP2C19ALDH1A1 | |
| SCHEMBL1335665 | 0.85 | ALDH1A1 (0.54) | CYP1A2CYP2C9TSHRCYP2C19ALDH1A1 | |
| SCHEMBL16386442 | 0.85 | CYP1A2 (0.56) | CYP1A2CYP2C9TSHRCYP2C19ALDH1A1 | |
| SCHEMBL12699010 | 0.85 | CYP1A2 (0.56) | CYP1A2CYP2C9TSHRCYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3240572-B1 | BENZAMIDE IMIDAZOPYRAZINE BTK INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-11-01 | — | — | EP | disclosed |
| US-10087188-B2 | Benzamide imidazopyrazine Btk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-10-02 | — | — | US | disclosed |
| US-20170362242-A1 | BENZAMIDE IMIDAZOPYRAZINE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-12-21 | — | — | US | disclosed |
| EP-3240572-A1 | BENZAMIDE IMIDAZOPYRAZINE BTK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-11-08 | — | — | EP | disclosed |
| EP-2376447-B1 | DIPEPTIDYL PEPTIDASE IV INHIBITORS | ORCHID PHARMA LTD (IN) | 2017-08-09 | — | — | EP | disclosed |
| EP-2685981-B1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRISTOL MYERS SQUIBB CO (US) | 2016-08-24 | — | — | EP | disclosed |
| WO-2016109223-A1 | BENZAMIDE IMIDAZOPYRAZINE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-07-07 | — | — | WO | disclosed |
| US-8921368-B2 | Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-30 | — | — | US | disclosed |
| US-8921368-B2 | Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-30 | — | — | US | disclosed |
| US-8921368-B2 | Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-30 | — | — | US | disclosed |
| US-20140011795-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRISTOL-MYERS SQUIBB COMPANY | 2014-01-09 | — | — | US | disclosed |
| US-20140011795-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRISTOL-MYERS SQUIBB COMPANY | 2014-01-09 | — | — | US | disclosed |
| US-20140011795-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRISTOL-MYERS SQUIBB COMPANY | 2014-01-09 | — | — | US | disclosed |
| US-8466145-B2 | Dipeptidyl peptidase IV inhibitors | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2013-06-18 | — | — | US | disclosed |
| US-20110257164-A1 | DIPEPTIDYL PEPTIDASE IV INHIBITORS | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2011-10-20 | — | — | US | disclosed |
| US-6596752-B1 | Small molecules that are potent inhibitors of alpha 4 beta 1 mediated adhesion to either VCAM or CS-1 and which could be useful for the treatment of inflammatory diseases. | TANABE SEIYAKU CO., LTD. (JP) | 2003-07-22 | — | — | US | disclosed |
| US-20030130349-A1 | Inhibitors of alpha 4beta1 mediated cell adhesion | TANABE SEIYAKU CO., LTD. | 2003-07-10 | — | — | US | disclosed |
| US-6482849-B1 | Inhibitors of α4β1 mediated cell adhesion | TANABE SEIYAKU CO., LTD. (JP) | 2002-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362242-A1 | BENZAMIDE IMIDAZOPYRAZINE BTK INHIBITORS | BTK, SYK, ABL1 | CYP1A2 2243/4885CYP2C9 1951/4885TSHR 1964/4885 |
| US-10087188-B2 | Benzamide imidazopyrazine Btk inhibitors | BTK, SYK, ABL1 | CYP1A2 2243/4885CYP2C9 1951/4885TSHR 1964/4885 |
| US-20140011795-A1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | JAK3, JAK1, JAK2 | CYP1A2 956/4885CYP2C9 966/4885TSHR 1543/4885 |
| US-20030130349-A1 | Inhibitors of alpha 4beta1 mediated cell adhesion | VCAM1, ICAM1, ITGB1 | CYP1A2 1888/4885CYP2C9 3367/4885TSHR 4066/4885 |
| US-20110257164-A1 | DIPEPTIDYL PEPTIDASE IV INHIBITORS | DPP4, DPP7, DPP3 | CYP1A2 429/4885CYP2C9 186/4885TSHR 1137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.